Orthoclone OKT3 Muromonab-CD3

Object Details

Ortho Pharmaceutical Corporation

Description (Brief): Orthoclone OKT3 prevents rejection of new tissues in patients who have received kidney grafts. It was the first drug created through monoclonal antibody technology to be approved for human use.; Monoclonal antibody technology uses specially made cells as tiny factories to pump out pure sources of a single antibody. Prior to its development, it was very difficult to isolate large amounts of a single antibody for therapeutic use.; Monoclonal antibody cells are created by fusing two cells of different origins. One cell, from a mouse's spleen, produces the antibody. The other cell, from a tumor, has the ability to replicate continuously. By fusing the two cells, a new cell is created which has the best characteristics of both-it produces the antibody and also grows quickly. These new cells produce large amounts of pure antibodies which are harvested for use in drugs like Orthoclone OKT3.; The object is a clear glass 5 mL ampule with a blue ring around the neck and a clear label with blue printing. It is housed in a formfitting plastic case with snap top and snap sides.
Location: Currently not on view

ca 1986

Physical Description: glass (container material); plastic (packaging material); murine monoclonal antibody muromonab-CDE, 5 mg (drug ingredient)
Measurements: overall: 3 3/8 in x 1 1/4 in x 1 1/4 in; 8.5725 cm x 3.175 cm x 3.175 cm; overall: 3 3/8 in x 1 1/4 in x 1 3/8 in; 8.5725 cm x 3.175 cm x 3.4925 cm

See more items in: Medicine and Science: Medicine; Health & Medicine; The Antibody Initiative; Biotechnology and Genetics; Recombinant Pharmaceuticals; Science & Mathematics; Antibody Initiative: Monoclonal Antibodies

National Museum of American History

GUID (Link to Original Record): https://n2t.net/ark:/65665/ng49ca746a8-6142-704b-e053-15f76fa0b4fa